KIT and gastrointestinal stromal tumor: In the current study (Study 1199), we retrospectively examined correlations between clinical outcomes and KIT/PDGFRA mutational status in a subset of imatinib-resistant or -intolerant patients with GIST participating in a worldwide, open-label treatment-use study (Study 1036) [28].